LPL and chronic kidney disease: The activity of lipoprotein lipase (LPL, the enzyme that hydrolyzes most TG in TRL) and the liver’s subsequent uptake of TRL remnants are inhibited by apolipoprotein C-III (apoC-III), whose plasma levels are significantly elevated in patients with CKD [17].